<DOC>
	<DOCNO>NCT00427102</DOCNO>
	<brief_summary>Rationale Study Oral mucositis major complication arise contemporary chemoradiation treatment patient head neck cancer . No effective therapy exist prevent complication population . MRX-1024 investigational agent demonstrate vitro vivo experiment potential exert protective effect normal mucosa cell , without interfere intend antitumor effect radiation . A pilot Phase 1 study MRX-1024 conduct India patient head neck cancer receive radiation alone radiation combination cisplatin carboplatin . MRX 1024 dose 100 mgkg give orally twice day , five day week radiation treatment cycle , well tolerate appear exert protective effect development severe mucositis . Twice daily dos MRX 1024 impose certain level inconvenience patient , clinic companion , general work flow within radiation oncology clinic . This study design study safety pharmacokinetics single daily dose twice daily dose regimen oral MRX 1024 give conjunction daily radiation fraction intermittent high-dose cisplatin patient high-risk recurrence head neck cancer follow surgical resection . The study also document incidence severity oral mucositis occur follow therapy . The result instrumental determine regimen MRX 1024 use subsequent definitive clinical trial .</brief_summary>
	<brief_title>MRX , Radiation , Chemotherapy Patients With Resected Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>TREATMENT PLAN Study Phases Each patient progress five study phase . MRX 1024 Cohorts , Dose Levels Treatment Five successive dose level plan . MRX 1024 Combination Treatment Phase Cohort Combination Treatment Phase MRX 1024 Schedule MRX 1024 Dose Level daily cohort 1 , 2 , 3 twice daily cohort 4 5 ) Initial Cohort Size 1 One daily dose give 30 minute dose RT 50 mg kg 3 patient 2 One daily dose give 30 minute dose RT 75 mg kg 3 patient 3 One daily dose give 30 minute dose RT 100 mg kg 3 patient 4a Two daily dos : one give 30 minute one give 30 minute dose RT 75 mg kg 3 patient 5a Two daily dos : one give 30 minute one give 30 minute dose RT 100 mg kg 3 patient Because logistics deliver radiation therapy , two daily dos MRX 1024 give patient cohorts 4 5 approximately 75 90 minute apart . To ensure accurate compliant dosing , MRX-1024 treatment must administer clinic . Beginning Day 1 Week 1 Combination Phase , patient begin receive MRX 1024 conjunction radiation cisplatin carboplatin , chemotherapy . MRX 1024 give prior day 's radiation fraction , follow day 's radiation fraction patient treat cohort 4 5 . If schedule radiation treatment give , MRX 1024 dose give day . Dose escalation occur successive cohort indicate Table 5 , base rule dose level escalation describe Table 6 , . Intra-patient dose escalation permit . No dose adjustment MRX 1024 permit . If patient experience DLT precludes treatment MRX 1024 , MRX 1024 treatment discontinue . That patient continue study , receive radiation therapy cisplatin carboplatin , accord protocol , follow study Follow Up Phase . The next high dose level open enrollment : 1. precede dose level enrol three patient , 2. two patient complete Days 1 42 3. third patient complete four week Combination treatment 4. none patient experience dose limit toxicity . If one patient treat open dose level experience DLT interval , 3 patient must enrol six patient dose level must follow minimum 42 day interval describe decision make regard enrollment escalation next high cohort . If additional patient experience DLT cohort , next high cohort open enrollment . If great 2 patient cohort experience DLT , cohort consider exceeded maximum tolerable dose level . Three additional patient enrol next low cohort use treatment schedule The objective dose escalation scheme identify safe , tolerable potentially efficacious dose level use daily dose schedule potentially efficacious dose level use twice daily dose schedule MRX-1024 le 1 6 patient experience DLT . Dose Level Escalation Rules Number Patients cohort DLTa Given Dose Level Escalation Dose Rule 0 3 . Enter 3 patient next high dose level . If cohort 3 cohort 5 complete 0 3 patient experience DLT , enroll 3 additional patient respective cohort . great 2 Dose escalation stop . This dose declare exceeded maximum tolerable dose . Enroll 3 additional patient next low cohort use MRX 1024 dose schedule . If occurs cohort 1 , 25 mg kg use next low dose level . 1 3 Enter 3 patient cohort dose level . If 0 3 additional patient experience DLT , begin enrollment next high cohort . If 1 3 additional patient experience DLT dose escalation stop . This dose declare exceeded maximum tolerable dose . Enroll 3 additional patient next low cohort use MRX 1024 dose schedule . If occurs cohort 1 , use 25 mg kg next low dose level . Less 1 6 high tolerable dose level This generally Recommended Dose subsequent clinical trial . See Section 4.5 definition Dose-Limiting Toxicity If patient complete Combination Treatment Phase reason relate intolerance MRX 1024 , constitute DLT patient replace study . If patient complete Combination Treatment Phase reason unrelated MRX 1024 patient experience DLT , additional patient enrol study . Data original patient remain part study database patient 's adverse event experience use evaluate safety MRX 1024 dose level . After study end , additional analysis safety data perform evaluate potential alternate dose scheme . The dos use five dose level describe convert individual patient basis approximate fix dos also mg body surface area dose . Based additional analysis , prefer dose scheme recommend subsequent clinical trial . Radiation Therapy Radiation therapy begin Day 1 Week 1 Combination Treatment Phase . Radiation therapy administer use daily fraction 2 Gy give Monday Friday , five consecutive day week , follow two day therapy . Radiotherapy continue weekly fashion total plan radiation dose 60 66 Gy deliver 6-week period . The toxicology study MRX-1024 conduct expose animal maximum duration 27 day . Therefore MRX 1024 administer first five week radiation therapy . The sixth week radiation therapy accompany treatment MRX 1024 . Cisplatin Carboplatin Cisplatin administer intravenously Day 1 Week 1 , Day 1 Week 4 , Day 1 Week 7 use dose 100 mg per square meter body-surface area cisplatin AUC5 6 carboplatin . On day , preferred sequence treatment MRX 1024 Radiotherapy . This sequence allow MRX 1024 dose absorb patient potentially develop vomit chemotherapy . See Section 4.6 guideline regard use antiemetic conjunction cisplatin carboplatin dose . Cisplatin therapy include pre- post treatment hydration requirement accord standard practice within institution . An example hydration procedures follow : Prior receive cisplatin , patient must receive vigorous hydration diuresis . A suggested regimen pre-hydration 1 liter D5NS 2 4 hour mannitol 12.5 g intravenously bolus immediately prior cisplatin . Then cisplatin 100 mg m2 500 ml NS administer 1 2 hour additional 1 1.5 liter fluid give post-hydration . The type , volume , rate fluid administration may vary base patient 's clinical status ability handle hydration requirement . Carboplatin therapy also include pre- post-treatment hydration . For regimen allow 21 day recovery AUC 5-6 dose use . The carboplatin dose administer 250 mL NS 5 mg min mL 30 minute . The dose cisplatin give Day 1 Weeks 4 7 adjust base parameter show . Laboratory test use determine adjust cisplatin dose obtain within 3 day prior schedule cisplatin dose . For carboplatin , dose adjustment base laboratory test result obtain within 7 day prior carboplatin dose . Absolute neutrophil count less 1500 µl : Cisplatin hold ANC less 1500 µl . After ANC recovers value , cisplatin dose adjust base ANC nadir achieve follow precede cisplatin dose , show Table 7 . If ANC recover within 14 day third cisplatin dose schedule , patient complete final Follow-Up Visit without receive third dose cisplatin . For carboplatin , adjustment make neutrophil count less 1300 mm3 . Platelet count le 100,000 µl : Cisplatin carboplatin hold platelet count less 100,000µl . After platelet count recovers value , cisplatin dose adjust base platelet count nadir achieve follow precede cisplatin dose , show Table 7 . If platelet count recover within 14 day third cisplatin dose schedule , patient complete final Follow Up Visit without receive third dose cisplatin . Cisplatin Dose Adjustment Based Absolute Neutrophil Count Platelet Count Nadirs Following Preceding Cisplatin Dose Nadir percentage 100 Cisplatin Dose Give . Renal Toxicity : Cisplatin give serum creatinine great 1.6 mg dL . Reduce cisplatin dose transient rise serum creatinine show Table 8 . Adjustments carboplatin dose delay administration occur serum creatinine great 2.0 mg dL . Liver toxicity : An adjustment dose delay administration occur t. bili great 1.5 mg dL . Cisplatin Dose Adjustment Based Highest Serum Creatinine Value Obtained Following Preceding Cisplatin Dose Serum Creatinine Peak ( mg dL ) percentage 100 Cisplatin Dose Give . In patient whose serum creatinine return le 1.6 mg dL schedule day cisplatin treatment , carboplatin substitute continue 3 week interval lieu cisplatin . Neurotoxicity : Cisplatin discontinue follow sign neurotoxicity occur follow first dose cisplatin : Grade 3 hearing loss speech frequency range , Grade 3 myopathy , Grade 3 weakness , Grade 3 neuropathy , seizure paralysis . If Investigator 's opinion , say adverse event relate solely cisplatin , would qualify DLTs . If Investigator 's opinion , say adverse event may possibly relate co-administration MRX 1024 , would qualify DLTs .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Biopsyproved squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx ; Statuspost surgical resection primary disease meeting criterion postoperative radiotherapy chemotherapy evidence histologic extracapsular nodal extension , histologic involvement &gt; 2 regional lymph node , mucosal margin resection invasive cancer ( limited microscopic detection ) ; Able begin protocol treatment within 8 week first tumorrelated surgery ; Age &gt; 18 year . Because dose adverse event data currently available use MRX1024 combination radiotherapy cisplatin carboplatin , patient le 18 year age , child exclude study , eligible future pediatric Phase 1 combination study appropriate indication sufficient safety efficacy data adult available . Karnofsky Performance Status &gt; 70 ( Appendix I ) ; Normal organ marrow function define herein , determine laboratory value obtain within seven day prior receive first dose protocol treatment : Serum creatinine within institutional limit normal Creatinine clearance &gt; 50 Total bilirubin within institutional limit normal AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 time upper limit normal institution White blood cell count &gt; 3500 per cubic millimeter Absolute neutrophil count &gt; 1500 per cubic millimeter Platelet count &gt; 100,000 per cubic millimeter Ability understand willingness sign inform consent document accordance institutional guideline . Gross ( visible palpable ) disease leave surgical resection ; Prior chemotherapy radiation therapy head neck region ; Primary site lip , nasopharynx paranasal sinus ; Distant metastases ; Known malabsorption syndrome ; Pregnancy breastfeeding . The effect MRX1024 develop human fetus unknown time . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately ; Gastrointestinal tract disease deformity result inability take oral enteral medication nutrition ; Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , untreated new cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; History take investigational medication within 4 week prior receive first dose protocol treatment . Prior malignancy within previous 5 year , exclude nonmelanoma skin cancer cervical cancer treat local therapy . Known allergy sensitivity polysorbate 80 ( Tween ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Oral MRX-1024</keyword>
	<keyword>High-Dose Cisplatin Chemotherapy</keyword>
	<keyword>Standard Radiation Therapy</keyword>
</DOC>